Site 'Tertiary' Navigation:

Page 'Breadcrumb' Navigation:

Press Releases

 
Press Releases
  Date Title and Summary View
Aug 4, 2016
SALT LAKE CITY, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, ...
Jun 29, 2016
SALT LAKE CITY, June 29, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has received a Complete Re...
Jun 27, 2016
SALT LAKE CITY, June 27, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has been added to the Russ...
Jun 27, 2016
SALT LAKE CITY, June 27, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has been added to the Russell 3000® and Russell Global® Indexes, effective after the U.S. market opens on Monday June 27, 2016. Annual reconstitution of the Russell US indexes captures the 4,0...
May 9, 2016
SALT LAKE CITY, May 09, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company,...
May 2, 2016
SALT LAKE CITY, May 02, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for...
Apr 6, 2016
SALT LAKE CITY, April 06, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CE...
Mar 28, 2016
SALT LAKE CITY, March 28, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, a...
Mar 28, 2016
SALT LAKE CITY, March 28, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data f...
Mar 10, 2016
SALT LAKE CITY, March 10, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2015. Quarterly and Recent HighlightsAnnounced the acceptance of its 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") f...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase